Experimental study of the pharmacokinetics of rifabutin in liposomal form
Abstract
On mongrel male rats studied pharmacokinetics of rifabutin in liposomal form, the relative bioavailability and tissue distribution after intratracheal administration, evaluated pharmacokinetic linearity. To determine rifabutin in plasma and organs were developed and validated HPLC method with UV detection. In the course of the study established a new linear pharmacokinetics of liposomal form of rifabutin dose range 6.5-26 mg/kg, calculate the main pharmacokinetic parameters found that rifabutin intensively distributed in highly vascularized organs, its content in poorly vascularized organs is much lower. After injection the highest concentration of active substance is observed at the injection site, namely the lungs. Relative bioavailability of rifabutin in liposomal form in this experiment was 522%.
About the Authors
M. V. Carlin
JSC «Saint-Petersburg Institute of Pharmacy», St. Petersburg
Russian Federation
Russian Federation
V. M. Cosman
JSC «Saint-Petersburg Institute of Pharmacy», St. Petersburg
Russian Federation
Russian Federation
O. N. Pozharitskaya
JSC «Saint-Petersburg Institute of Pharmacy», St. Petersburg
Russian Federation
Russian Federation
A. N. Shikov
JSC «Saint-Petersburg Institute of Pharmacy», St. Petersburg
Russian Federation
Russian Federation
M. N. Makarova
JSC «Saint-Petersburg Institute of Pharmacy», St. Petersburg
Russian Federation
Russian Federation
V. G. Makarov
JSC «Saint-Petersburg Institute of Pharmacy», St. Petersburg
Russian Federation
Russian Federation
V. Y. Balabanyan
LLC «Technology of medicines», Moscow region, Khimki
Russian Federation
Russian Federation
References
1. Gaspar M.M., Neves S., Portaels F., Pedrosa J., Silva T.M., Cruz M.E. Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection. // Antimicrob. Agents Chemother. 2000. Vol. 44, № 3. Р. 292—306.
2. Gaspar M.M., Cruz. A., Penha A.F., Reymao J., Sousa A.C., Eleuterio C.V., et al. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. // International Journal of Antimicrobial Agents. 2008. Vol.31, P. 37—45.
3. Kulkarni P.R., Yadav J.D., Vaidya K.A. Liposomes: a novel drug delivery system. // International J. of current pharmaceutical research. 2011. Vol.3, №.2. P. 10-18.
4. Исмаилова Т.К., Жилченко Е.Б., Ефременко Д.В., Головченко Т.В., Малецкая О.В., Одинец А.В., Кремнева Г.М., Романова Л.В. Эффективность применения липосомальных форм антибиотиков при лечении некоторых инфекционных заболеваний в эксперименте. // Вестник ВолГМУ. 2007. Т. 21, №1. С. 64-67.
5. Пиотровский В.К. Метод статистических моментов и интегральные модельно-независимые параметры фармакокинетики. // Фармакология и токсикология. 1986. Т. 49, №5. С.118-127.
6. Guideline on bioanalytical method validation. EMEA/CHMP/EWP192217/2009, London, Committee for medicinal products for human use (CHMP), 2011.
7. ICH, Q2A, Harmonized tripartite guideline, text on validation of analytical procedures, IFPMA, in: Proceedings of the International Conference on Harmonization, Geneva, March 1994, pp. 1 — 5.
8. ICH, Q2B, Harmonized tripartite guideline, validation of analytical procedure: methodology, IFPMA, in: Proceedings of the International Conference on Harmonization, Geneva, March 1996, pp. 1—8.
9. Guidance for Industry: Bioanalytical method for validation. — Rockville, MD, U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Center for veterinary medicine, 2001.
Review
For citations:
Carlin M.V., Cosman V.M., Pozharitskaya O.N., Shikov A.N., Makarova M.N., Makarov V.G., Balabanyan V.Y. Experimental study of the pharmacokinetics of rifabutin in liposomal form. Pharmacokinetics and Pharmacodynamics. 2013;(2):37-41. (In Russ.)
Views:
801
Email this article 